The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors.
 
Ecaterina Elena Dumbrava
Consulting or Advisory Role - Bolt Biotherapeutics
Research Funding - Aileron Therapeutics (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Bolt Biotherapeutics (Inst); Compugen (Inst); Gateway Foundation (Inst); Immunocore (Inst); Immunomedics/Gilead (Inst); Mereo BioPharma 5 (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); TRACON Pharma (Inst); Triumvira Immunologics, Inc (Inst); Unum Therapeutics (Inst)
 
Michael Cecchini
Stock and Other Ownership Interests - Parthenon Therapeutics
Honoraria - Aptitude Health; AstraZeneca; Bayer; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Elevation Oncology; GRAIL; Macrogenics; Seagen
 
Jon Zugazagoitia
Honoraria - AstraZeneca Spain; Bristol-Myers Squibb/Celgene; Guardant Health; NanoString Technologies; Pfizer; Roche/Genentech; Sanofi/Regeneron
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; Guardant Health; Novartis; Novartis; Pfizer; Sanofi/Regeneron
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb/Celgene; Guardant Health; MSD Oncology; NanoString Technologies; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene; Roche/Genentech
 
Juanita Suzanne Lopez
Consulting or Advisory Role - Basilea; CureTeq; Ellipses Pharma; Genmab; Novartis; Pierre Fabre; Roche/Genentech
Research Funding - Astex Pharmaceuticals (Inst); Basilea (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Basilea; Roche/Genentech
 
Dirk Jäger
Leadership - Bristol-Myers Squibb Stiftung Immunonkologie
Honoraria - Bristol-Myers Squibb; Georg Thieme Verlag; MSD; SKK Kliniken Heilbronn GmbH; Terrapinn; Touch Medical Media
Consulting or Advisory Role - CureVac; Definiens; F. Hoffmann LaRoche; Genmab; Life Science Inkubator; Oncolytics; OncoOne; Research GmbH; VAXIMM
Expert Testimony - Else Kröner-Fresenius-Stiftung; Expert opinions for courts; NordForsk; Schering Stiftung; Wilhlem Sander-Stiftung
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; IKTZ; ORYX; PAREXEL; Roche Glycart AG
Other Relationship - CureVac; Definiens; F. Hoffmann LaRoche; Genmab; Life Science Inkubator; Oncolytics; OncoOne; Research GmbH; VAXIMM
 
Marc Oliva
Honoraria - Bristol-Myers Squibb/Pfizer; Bristol-Myers Squibb/Pfizer; Merck; MSD Oncology; Transgene
Consulting or Advisory Role - Merck KGaA
Research Funding - ALX Oncology (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Merck; MSD Oncology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Pfizer; Merck; MSD Oncology
Other Relationship - Merck; MSD Oncology
 
Sebastian Ochsenreither
Honoraria - AstraZeneca; Bristol-Myers Squibb; Janssen; Merck; MSD
Consulting or Advisory Role - Immunaccel; Janssen; MSD
Speakers' Bureau - MSD
Patents, Royalties, Other Intellectual Property - Patent: Cyclin A1 as T-cell target
Travel, Accommodations, Expenses - Janssen; Merck; Pfizer
 
Valentina Gambardella
No Relationships to Disclose
 
Ki Y. Chung
Research Funding - epizyme (Inst); MedImmune (Inst)
 
Federico Longo
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Ferrer; Lilly; Merck; MSD; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Lilly; MSD; Roche; SERVIER
Travel, Accommodations, Expenses - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Ferrer; Lilly; Merck; MSD; Roche; Sanofi; SERVIER
 
Albiruni Ryan Abdul Razak
Consulting or Advisory Role - Adaptimmune; Bayer; GlaxoSmithKline; Inhibrx; Medison
Research Funding - 23 and Me; Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Deciphera; Frontier Therapeutics; GlaxoSmithKline; Iterion Therapeutics; Karyopharm Therapeutics; MedImmune; Merck; Neoleukin Therapeutics; Pfizer; Rain Therapeutics; Roche/Genentech; Symphogen
Expert Testimony - Medison
 
Martin Wermke
Honoraria - Amgen; Boehringer Ingelheim; GWT; Janssen; Lilly; Merck Serono; Merck Serono; Novartis; SYNLAB
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; ImCheck therapeutics; immatics; ISA Pharmaceuticals; Lilly; Novartis
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; GEMoaB; immatics; Merck Serono; Pfizer; Sanofi/Aventis
 
T.R. Jeffry Evans
Honoraria - Ascelia (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst)
Consulting or Advisory Role - Karus Therapeutics (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); United Medical (Inst)
Research Funding - Adaptimmune (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Athenex (Inst); Avacta Life Sciences (Inst); Basilea (Inst); Beigene (Inst); Berg Pharma (Inst); Bicycle Therapeutics (Inst); BiolineRx (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Codiak BioSciences (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunocore (Inst); iOnctura (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Medivir (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); Modulate Pharma (Inst); Novartis (Inst); Nucana (Inst); Nurix (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Sierra Pharma (Inst); Starpharma (Inst); T3 Pharmaceuticals (Inst); UCB (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Medivir (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; Eisai; Merck Sharp & Dohme; Nucana; Pierre Fabre
Other Relationship - Genmab (Inst)
 
Natalie Cook
Employment - CellCentric (I)
Stock and Other Ownership Interests - CellCentric (I)
Honoraria - Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Novartis (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Starpharma (Inst); Taiho Pharmaceutical (Inst); Tarveda Therapeutics (Inst); UCB (Inst)
(OPTIONAL) Uncompensated Relationships - Roche
 
Maxime Chenard-Poirier
No Relationships to Disclose
 
Radost Pencheva
Employment - Bayer
 
David Schaer
Employment - Bayer
 
Thomas Wagener
Employment - Bayer
 
Andrea Wagner
Employment - Bayer
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - Basilea; Bicycle Therapeutics; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); F-star (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)